

Since its launch in 1995, Taiwan's National Health Insurance (NHI) has provided comprehensive health coverage to all citizens under a model of self-help and mutual assistance. By ensuring equitable, accessible, and efficient medical services, the NHI has reduced the burden of illness-related poverty and become a global exemplar of universal healthcare.

Recognizing the rapid advancements in breast cancer treatment—including new medications, precision medicine, and genetic testing—the National Health Insurance Administration (NHIA) is committed to continually improving the quality of care for breast cancer patients. The NHIA actively works to include clinically beneficial diagnostic tests and therapeutic drugs in NHI reimbursement coverage, striving to align with international treatment standards while maintaining financial sustainability.

To further enhance care, the NHIA has convened a breast cancer expert panel to refine the Pay-for-Performance (P4P) program for breast cancer. The program's goals include expanding hospital participation, enrolling at least 80% of newly diagnosed patients, and improving care outcomes. Targeting both newly diagnosed and first-relapsed cases—including male patients and all cancer stages—the program offers coordinated case management and follow-up care delivered by multidisciplinary clinical teams.

Looking ahead, through the dual strategy of expanding drug coverage and strengthening care delivery systems, Taiwan aims to build a more comprehensive and higher-quality healthcare framework for all breast cancer patients.